D-NMAPPD (Synonyms: (1R,2R)-B13)

Name: D-NMAPPD
Brand: MedChemExpress
SKU: HY-124962
Rating: 4.5 (1 reviews)

Cat. No.: HY-124962 Purity: 99.74%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs.

For research use only. We do not sell to patients.

D-NMAPPD Chemical Structure

CAS No. : 35922-06-6

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE D-NMAPPD

•Pathog Dis. 2024 Jul 19:ftae016. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

View All Isoforms

AMPA Receptor NMDA Receptor Kainate Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	1.5 μM Compound: B-13	Cytotoxicity against human HL60 cells assessed as growth inhibition by trypan blue dye exclusion assay Cytotoxicity against human HL60 cells assessed as growth inhibition by trypan blue dye exclusion assay	[PMID: 23312611]
MCF7	IC₅₀	14 μM Compound: B13	Antiproliferative activity against human MCF7 cells after 48 hrs Antiproliferative activity against human MCF7 cells after 48 hrs	[PMID: 17869115]
MCF7	IC₅₀	19.6 μM Compound: B13	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19217788]
MCF7	IC₅₀	27.7 μM Compound: B13	Inhibition of ACDase in human MCF7 cell lysate using [9,10-3H] De-C16-Cer substrate after 1 hr by scintillation counting analysis Inhibition of ACDase in human MCF7 cell lysate using [9,10-3H] De-C16-Cer substrate after 1 hr by scintillation counting analysis	[PMID: 25456083]
MCF7	IC₅₀	35.59 μM Compound: (1R,2R)-B13; D-NMAPPD	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 33461145]
MCF7	IC₅₀	37.01 μM Compound: (1R,2R)-B13; D-NMAPPD	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33461145]
MCF7	IC₅₀	42.27 μM Compound: (1R,2R)-B13; D-NMAPPD	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 33461145]
Sf9	IC₅₀	120 μM Compound: B-13	Inhibition of recombinant human nCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate after 2 hrs by fluorescence assay Inhibition of recombinant human nCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate after 2 hrs by fluorescence assay	[PMID: 22989912]

In Vitro

In rat hippocampal slices, D-NMAPPD exhibit increased N-methyl-D-aspartate (NMDA) receptor-mediated field excitatory postsynaptic potentials (fEPSPs) in CA1 synapses^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

422.56

Formula

C₂₃H₃₈N₂O₅

CAS No.

35922-06-6

Appearance

Solid

Color

White to off-white

SMILES

OC[C@H]([C@@H](C1=CC=C(C=C1)[N+]([O-])=O)O)NC(CCCCCCCCCCCCC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (473.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3665 mL	11.8326 mL	23.6653 mL
5 mM	0.4733 mL	2.3665 mL	4.7331 mL
10 mM	0.2367 mL	1.1833 mL	2.3665 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (268 KB) SDS (251 KB)

COA (242 KB) HNMR (136 KB) RP-HPLC (140 KB) LCMS (384 KB)

Handling Instructions (2659 KB)

References

[1]. Marie-Elaine Laurier-Laurin, et al.Blockade of lysosomal acid ceramidase induces GluN2B-dependent Tau phosphorylation in rat hippocampal slices. Neural Plast. 2014;2014:196812. [Content Brief]

[2]. M Selzner, et al.Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001 Feb 1;61(3):1233-40. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3665 mL	11.8326 mL	23.6653 mL	59.1632 mL
	5 mM	0.4733 mL	2.3665 mL	4.7331 mL	11.8326 mL
	10 mM	0.2367 mL	1.1833 mL	2.3665 mL	5.9163 mL
	15 mM	0.1578 mL	0.7888 mL	1.5777 mL	3.9442 mL
	20 mM	0.1183 mL	0.5916 mL	1.1833 mL	2.9582 mL
	25 mM	0.0947 mL	0.4733 mL	0.9466 mL	2.3665 mL
	30 mM	0.0789 mL	0.3944 mL	0.7888 mL	1.9721 mL
	40 mM	0.0592 mL	0.2958 mL	0.5916 mL	1.4791 mL
	50 mM	0.0473 mL	0.2367 mL	0.4733 mL	1.1833 mL
	60 mM	0.0394 mL	0.1972 mL	0.3944 mL	0.9861 mL
	80 mM	0.0296 mL	0.1479 mL	0.2958 mL	0.7395 mL
	100 mM	0.0237 mL	0.1183 mL	0.2367 mL	0.5916 mL

D-NMAPPD Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

D-NMAPPD35922-06-6(1R,2R)-B13iGluRIonotropic glutamate receptorsacid ceramidaseNMDA receptoranticancer effecsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

D-NMAPPD (Synonyms: (1R,2R)-B13)

Customer Review

D-NMAPPD Related Antibodies

1 Publications Citing Use of MCE D-NMAPPD

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All iGluR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

D-NMAPPD Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

D-NMAPPD Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report